VivoSeq
Oncology

Locally Advanced Solid Tumor

1

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Locally Advanced Solid Tumor is an early-stage landscape with 1 program across 6 companies. The most active players are Ipsen, Merck & Co., EMD Serono Research & Development Institute, Inc..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ipsen logo

Ipsen

1 program

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalEMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

0 programs

PreclinicalK

Kadmon, a Sanofi Company

0 programs

PreclinicalW

Wuhan YZY Biopharma Co., Ltd.

0 programs

PreclinicalB

Betta Pharmaceuticals Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

IPN60300

Ipsen

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

16

clinical trials

Completed9 · 56%
Unknown status3 · 19%
Recruiting2 · 13%
Terminated1 · 6%
Suspended1 · 6%

Clinical Trials

Trial Activity

16 trials

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Recruiting·RRemeGen Co., Ltd.·Phase 1·NCT05940896·24 enrolled
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.
Recruiting·Ipsen logoIpsen·Preclinical·NCT07213817·114 enrolled
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01943461·57 enrolled
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Completed·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 1·NCT02517398·600 enrolled
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT02775292·1 enrolled
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors
Completed·National Cancer Institute (NCI)·Phase 1·NCT00331955·40 enrolled
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Completed·EMD Serono Research & Development Institute, Inc. logoEMD Serono Research & Development Institute, Inc.·Phase 1·NCT01772004·1,756 enrolled
QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
Completed·IImmunityBio, Inc.·Phase 1·NCT03027128·6 enrolled
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02699515·114 enrolled
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
Completed·WWuhan YZY Biopharma Co., Ltd.·Phase 1·NCT05028556·50 enrolled
Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
Completed·AAgenus Inc.·Phase 1/2·NCT03495882·154 enrolled
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Suspended·MMetastatix, Inc.·Phase 1·NCT00591682·27 enrolled
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Terminated·KKadmon, a Sanofi Company·Phase 1·NCT04242147·45 enrolled
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03774979·193 enrolled
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03710265·206 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)